The global Biosimilars market size was valued at US$ 5602.9 million in 2023. With growing demand in downstream market, the Biosimilars is forecast to a readjusted size of US$ 18570 million by 2030 with a CAGR of 18.7% during review period.
The research report highlights the growth potential of the global Biosimilars market. Biosimilars are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Biosimilars. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Biosimilars market.
A biosimilar is a biologic medical product highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Biosimilars market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Biosimilars market. It may include historical data, market segmentation by Type (e.g., Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), Recombinant Glycosylated Proteins), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Biosimilars market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Biosimilars market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Biosimilars industry. This include advancements in Biosimilars technology, Biosimilars new entrants, Biosimilars new investment, and other innovations that are shaping the future of Biosimilars.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Biosimilars market. It includes factors influencing customer ' purchasing decisions, preferences for Biosimilars product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Biosimilars market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Biosimilars market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Biosimilars market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Biosimilars industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Biosimilars market.
麻豆原创 Segmentation:
Biosimilars market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Recombinant Glycosylated Proteins
Segmentation by application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Novartis
Biocon
Biogen
Fresenius Kabi AG
Boehringer Ingelheim
Merck KgaA
Mylan
Eli Lilly
Teva Pharmaceutical
Dr. Reddy's Laboratories
Amgen
Celltrion
Samsung Biologics
Roche
Probiomed
Apotex
Chong Kun Dang
JCR Pharmaceuticals
Gan & Lee Pharmaceuticals
Gedeon Richter
Biocad
Coherus Bioscience
Stada Arzneimittel AG
Key Questions Addressed in this Report
What is the 10-year outlook for the global Biosimilars market?
What factors are driving Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biosimilars market opportunities vary by end market size?
How does Biosimilars break out type, application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Biosimilars Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Biosimilars by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Biosimilars by Country/Region, 2019, 2023 & 2030
2.2 Biosimilars Segment by Type
2.2.1 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
2.2.2 Recombinant Glycosylated Proteins
2.3 Biosimilars Sales by Type
2.3.1 Global Biosimilars Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Biosimilars Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Biosimilars Sale Price by Type (2019-2024)
2.4 Biosimilars Segment by Application
2.4.1 Oncology
2.4.2 Blood Disorders
2.4.3 Growth Hormonal Deficiency
2.4.4 Chronic and Autoimmune Disorders
2.4.5 Others
2.5 Biosimilars Sales by Application
2.5.1 Global Biosimilars Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Biosimilars Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Biosimilars Sale Price by Application (2019-2024)
3 Global Biosimilars by Company
3.1 Global Biosimilars Breakdown Data by Company
3.1.1 Global Biosimilars Annual Sales by Company (2019-2024)
3.1.2 Global Biosimilars Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Biosimilars Annual Revenue by Company (2019-2024)
3.2.1 Global Biosimilars Revenue by Company (2019-2024)
3.2.2 Global Biosimilars Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Biosimilars Sale Price by Company
3.4 Key Manufacturers Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biosimilars Product Location Distribution
3.4.2 Players Biosimilars Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Biosimilars by Geographic Region
4.1 World Historic Biosimilars 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Biosimilars Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Biosimilars Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Biosimilars 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Biosimilars Annual Sales by Country/Region (2019-2024)
4.2.2 Global Biosimilars Annual Revenue by Country/Region (2019-2024)
4.3 Americas Biosimilars Sales Growth
4.4 APAC Biosimilars Sales Growth
4.5 Europe Biosimilars Sales Growth
4.6 Middle East & Africa Biosimilars Sales Growth
5 Americas
5.1 Americas Biosimilars Sales by Country
5.1.1 Americas Biosimilars Sales by Country (2019-2024)
5.1.2 Americas Biosimilars Revenue by Country (2019-2024)
5.2 Americas Biosimilars Sales by Type
5.3 Americas Biosimilars Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biosimilars Sales by Region
6.1.1 APAC Biosimilars Sales by Region (2019-2024)
6.1.2 APAC Biosimilars Revenue by Region (2019-2024)
6.2 APAC Biosimilars Sales by Type
6.3 APAC Biosimilars Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Biosimilars by Country
7.1.1 Europe Biosimilars Sales by Country (2019-2024)
7.1.2 Europe Biosimilars Revenue by Country (2019-2024)
7.2 Europe Biosimilars Sales by Type
7.3 Europe Biosimilars Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biosimilars by Country
8.1.1 Middle East & Africa Biosimilars Sales by Country (2019-2024)
8.1.2 Middle East & Africa Biosimilars Revenue by Country (2019-2024)
8.2 Middle East & Africa Biosimilars Sales by Type
8.3 Middle East & Africa Biosimilars Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biosimilars
10.3 Manufacturing Process Analysis of Biosimilars
10.4 Industry Chain Structure of Biosimilars
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biosimilars Distributors
11.3 Biosimilars Customer
12 World Forecast Review for Biosimilars by Geographic Region
12.1 Global Biosimilars 麻豆原创 Size Forecast by Region
12.1.1 Global Biosimilars Forecast by Region (2025-2030)
12.1.2 Global Biosimilars Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Biosimilars Forecast by Type
12.7 Global Biosimilars Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Biosimilars Product Portfolios and Specifications
13.1.3 Pfizer Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Biosimilars Product Portfolios and Specifications
13.2.3 Novartis Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Biocon
13.3.1 Biocon Company Information
13.3.2 Biocon Biosimilars Product Portfolios and Specifications
13.3.3 Biocon Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Biocon Main Business Overview
13.3.5 Biocon Latest Developments
13.4 Biogen
13.4.1 Biogen Company Information
13.4.2 Biogen Biosimilars Product Portfolios and Specifications
13.4.3 Biogen Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Biogen Main Business Overview
13.4.5 Biogen Latest Developments
13.5 Fresenius Kabi AG
13.5.1 Fresenius Kabi AG Company Information
13.5.2 Fresenius Kabi AG Biosimilars Product Portfolios and Specifications
13.5.3 Fresenius Kabi AG Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Fresenius Kabi AG Main Business Overview
13.5.5 Fresenius Kabi AG Latest Developments
13.6 Boehringer Ingelheim
13.6.1 Boehringer Ingelheim Company Information
13.6.2 Boehringer Ingelheim Biosimilars Product Portfolios and Specifications
13.6.3 Boehringer Ingelheim Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Boehringer Ingelheim Main Business Overview
13.6.5 Boehringer Ingelheim Latest Developments
13.7 Merck KgaA
13.7.1 Merck KgaA Company Information
13.7.2 Merck KgaA Biosimilars Product Portfolios and Specifications
13.7.3 Merck KgaA Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Merck KgaA Main Business Overview
13.7.5 Merck KgaA Latest Developments
13.8 Mylan
13.8.1 Mylan Company Information
13.8.2 Mylan Biosimilars Product Portfolios and Specifications
13.8.3 Mylan Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Mylan Main Business Overview
13.8.5 Mylan Latest Developments
13.9 Eli Lilly
13.9.1 Eli Lilly Company Information
13.9.2 Eli Lilly Biosimilars Product Portfolios and Specifications
13.9.3 Eli Lilly Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Eli Lilly Main Business Overview
13.9.5 Eli Lilly Latest Developments
13.10 Teva Pharmaceutical
13.10.1 Teva Pharmaceutical Company Information
13.10.2 Teva Pharmaceutical Biosimilars Product Portfolios and Specifications
13.10.3 Teva Pharmaceutical Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Teva Pharmaceutical Main Business Overview
13.10.5 Teva Pharmaceutical Latest Developments
13.11 Dr. Reddy's Laboratories
13.11.1 Dr. Reddy's Laboratories Company Information
13.11.2 Dr. Reddy's Laboratories Biosimilars Product Portfolios and Specifications
13.11.3 Dr. Reddy's Laboratories Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Dr. Reddy's Laboratories Main Business Overview
13.11.5 Dr. Reddy's Laboratories Latest Developments
13.12 Amgen
13.12.1 Amgen Company Information
13.12.2 Amgen Biosimilars Product Portfolios and Specifications
13.12.3 Amgen Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Amgen Main Business Overview
13.12.5 Amgen Latest Developments
13.13 Celltrion
13.13.1 Celltrion Company Information
13.13.2 Celltrion Biosimilars Product Portfolios and Specifications
13.13.3 Celltrion Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Celltrion Main Business Overview
13.13.5 Celltrion Latest Developments
13.14 Samsung Biologics
13.14.1 Samsung Biologics Company Information
13.14.2 Samsung Biologics Biosimilars Product Portfolios and Specifications
13.14.3 Samsung Biologics Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Samsung Biologics Main Business Overview
13.14.5 Samsung Biologics Latest Developments
13.15 Roche
13.15.1 Roche Company Information
13.15.2 Roche Biosimilars Product Portfolios and Specifications
13.15.3 Roche Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Roche Main Business Overview
13.15.5 Roche Latest Developments
13.16 Probiomed
13.16.1 Probiomed Company Information
13.16.2 Probiomed Biosimilars Product Portfolios and Specifications
13.16.3 Probiomed Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Probiomed Main Business Overview
13.16.5 Probiomed Latest Developments
13.17 Apotex
13.17.1 Apotex Company Information
13.17.2 Apotex Biosimilars Product Portfolios and Specifications
13.17.3 Apotex Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Apotex Main Business Overview
13.17.5 Apotex Latest Developments
13.18 Chong Kun Dang
13.18.1 Chong Kun Dang Company Information
13.18.2 Chong Kun Dang Biosimilars Product Portfolios and Specifications
13.18.3 Chong Kun Dang Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Chong Kun Dang Main Business Overview
13.18.5 Chong Kun Dang Latest Developments
13.19 JCR Pharmaceuticals
13.19.1 JCR Pharmaceuticals Company Information
13.19.2 JCR Pharmaceuticals Biosimilars Product Portfolios and Specifications
13.19.3 JCR Pharmaceuticals Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 JCR Pharmaceuticals Main Business Overview
13.19.5 JCR Pharmaceuticals Latest Developments
13.20 Gan & Lee Pharmaceuticals
13.20.1 Gan & Lee Pharmaceuticals Company Information
13.20.2 Gan & Lee Pharmaceuticals Biosimilars Product Portfolios and Specifications
13.20.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Gan & Lee Pharmaceuticals Main Business Overview
13.20.5 Gan & Lee Pharmaceuticals Latest Developments
13.21 Gedeon Richter
13.21.1 Gedeon Richter Company Information
13.21.2 Gedeon Richter Biosimilars Product Portfolios and Specifications
13.21.3 Gedeon Richter Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Gedeon Richter Main Business Overview
13.21.5 Gedeon Richter Latest Developments
13.22 Biocad
13.22.1 Biocad Company Information
13.22.2 Biocad Biosimilars Product Portfolios and Specifications
13.22.3 Biocad Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.22.4 Biocad Main Business Overview
13.22.5 Biocad Latest Developments
13.23 Coherus Bioscience
13.23.1 Coherus Bioscience Company Information
13.23.2 Coherus Bioscience Biosimilars Product Portfolios and Specifications
13.23.3 Coherus Bioscience Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.23.4 Coherus Bioscience Main Business Overview
13.23.5 Coherus Bioscience Latest Developments
13.24 Stada Arzneimittel AG
13.24.1 Stada Arzneimittel AG Company Information
13.24.2 Stada Arzneimittel AG Biosimilars Product Portfolios and Specifications
13.24.3 Stada Arzneimittel AG Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.24.4 Stada Arzneimittel AG Main Business Overview
13.24.5 Stada Arzneimittel AG Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
